Roche provides innovative women’s health diagnostic tests and solutions to help assess risk, identify disease, and monitor patients with specific solutions intended to meet the unique needs of women at every stage of life.
Our differentiated assay offerings on a range of technology platforms are proven to provide meaningful results and reliable decision-making information to help predict and determine next steps, and move towards more individualized patient care and disease prevention when possible.
We deliver innovations that give healthcare professionals the tools and confidence they need to support quality care for women, meeting or setting new standards for clinical guideline recommendations. Roche has diagnostic solutions, including high medical value tests, for:
Women all over the world should have the chance to live their best lives, and good health is an essential place to start. Roche seeks to empower women by making sure the right test is used at the right time, for well-informed decision-making.
Women are the backbone of most family and society ecosystems. They are a critical part of healthcare decision-making for themselves and their loved ones, yet they often face significant barriers to healthcare access and quality treatment.
Social and economic disadvantages, gender bias, and discrimination negatively impact women’s health outcomes.1 Here are some of the major health conditions and diseases that women face worldwide:
Reproductive and Sexual Health
Women’s cancers
Infectious diseases
Bone health
At Roche, we are committed to bringing more innovations in women’s health diagnostics, regardless of where a woman lives or where she is from. Every woman deserves to have full control over her health, sexual and reproductive choices and should feel empowered to take an active and informed role in her own wellness, from prevention through to treatment.
Today, women are faced with inequities in treatment and care due in large part to historically insufficient research in the area of women’s health. Recognizing the critical need to overcome this disparity, Roche launched XProject, an ongoing initiative to drive meaningful change in women’s health. With the support and collaboration of key partners, Roche is conducting new research to close the health data gender gap and create a future where women have an equal opportunity to access the right information, the right diagnosis, and the right treatment.
Roche is leading the way in providing a broad range of reliable diagnostic solutions for sexually transmitted infections (STIs), including HIV and HPV.
We provide diagnostic, data and insights, and support solutions that enable confident decision-making to help enhance patient care. Our assays are trusted by customers worldwide, with over 29 billion tests completed in 2023.16
From fertility, pregnancy and prenatal testing, through infectious diseases, to female cancers and bone health solutions, we truly touch women at every stage of their lives with Roche tests.
Breast cancer: More than 6.5 million women received Roche predictive diagnostics tests to aid in breast cancer treatment decisions
Cervical cancer: More than 30 million women gained information about risk from Roche’s cervical cancer portfolio for screening and disease management
Fertility: More than 1 million women explored AMH/AMH Plus as an indication of ovarian reserve in the quest to potentially build a family
Preeclampsia: About 500,000 pregnant women were properly managed with preeclampsia ratio tests
Noninvasive prenatal testing (NIPT): Over 2 million expectant mothers were given accurate information about their babies
X represents the female chromosome that warrants more investigation in order for us to achieve our goal to make a difference for the health of women. We all have an opportunity to be better.
Currently, we work with individuals, organizations, industry, government and more to identify and remove barriers in healthcare systems so that every woman can fully and equitably access care, no matter where they are in the world.
Offering medical value starts with proper clinical study enrollment, addressing patient stories of inequity, and understanding where we can best achieve our goals.
Note that we use the terms “woman” and “women” referring to people who biologically have two x chromosomes (xx). However, inclusivity is at the core of XProject and we recognize that these individuals may not all identify as female. We respect that gender identities are diverse and are striving for an equitable health system for all.
For over 125 years, Roche has been a leading force in healthcare. Driven by a deep understanding of science and medicine, we continue to pioneer innovation to shape a healthier tomorrow.
XProject is a long-term commitment and ongoing initiative aimed at closing the gaps in women’s health through partnerships, funding, and action, leading to better health outcomes for everyone. See how you can join or help support this initiative.
We offer a portfolio of prenatal diagnostics for checking in on the in-utero baby, including a blood test that can non-invasively define the risk of chromosomal abnormalities.
References: